Hsing-Mao Chu

Company: Meds.com

Job title: Chief Executive Officer

Seminars:

Exploring ADCs With Site-Specific Conjugation, DAR of 8 or 12, & Payloads With Dual Drugs to Turbocharge ADC Innovation 11:00 am

Discuss the “CHO-TEM” technology, combining CHO Pharma’s “glycan modification” technology, and T-E Meds’ “drug bundles” technology Outline how antibody molecule glycans are modified with one enzyme to create 4 azido groups, to which 4 drug bundles each with 2 or 3 drugs of two categories are linked Learn how to produce homogeneous ADCs with high…Read more

day: Day One